A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

Inclusion criteria: \- Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) treatment is appropriate Exclusion criteria: * Treatment with chemotherapy, hormonal therapy, radiotherapy, surgery, or an investigational agent within 28 days * Eastern Cooperative Oncology Group (ECOG) \>1 * Need for a major surgical procedure or radiation therapy during the study * Diagnosis of squamous-cell lung cancer * Cumulative radiation therapy to \> 25% of the total bone marrow * History of brain metastases * Inadequate organ and bone marrow function * Uncontrolled hypertension * Evidence of clinically significant bleeding diathesis or underlying coagulopathy * Prior FOLFIRI treatment but have not been appropriate for safety reasons * Patients with known Gilbert's syndrome The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.